JCC: Smoking may reduce the effectiveness of anti-TNF therapy in Crohn's disease.

The background and objectives are well known, and smoking worsens the prognosis of Crohn's disease (CD).
Does smoking also lead to a decrease in the effectiveness of anti-TNF therapy in Crohn's disease? This study explores the relationship between smoking and anti-TNF therapy to induce clinical response or remission.
method researchers searched databases such as MEDLINE, EMBASE, PubMed and Cochrane CENTRAL for studies on the effects of smoking on short-term clinical responses to CD patients and the effects of anti-TNF treatment (16 weeks after first treatment).
then a meta-analysis was performed.
results The researchers included 18 observational studies and 3 randomized controlled trials (RCTs), similar clinical response rates between smokers and nonsmokers (never-smokers or never smokers) (observational study RR: 0.96; 95% CI:0.88, 1.05; RCT RRT: 1.09; 95% CI:0.84, 1.41).
when limited to studies that clearly define smoking exposure, smokers who received anti-TNF treatment were more difficult to achieve a clinical response than nonsmokers (smokers are defined as 5 cigarettes per day/6 months per day, RR: 0.63; 95% CI: 0.48, 0.83; RR: 0.81; 95% CI: 0.71, 0.93).
concluded that the study found a significant correlation between smoking and the ability to induce short-term clinical response and remission of infexivirus or Adamu monotomatod.
quitting smoking can improve clinical outcomes when CD patients receive effective treatment, including anti-TNF drugs.
.